Markets:

Overview

News

Currencies

International

Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.515 -0.285 (-4.91%)

Delayed Quote Updated: 12:18 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 Next >

Gapping stocks in Wednesday's session ↗

September 16, 2026

Via Chartmill

Alvotech Q2 Earnings Call Highlights ↗

August 20, 2026

Alvotech (NASDAQ:ALVO) said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed...

Via MarketBeat

Topics Earnings

Alvotech Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Alvotech (NASDAQ:ALVO) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga...

Via Benzinga

Topics Earnings

These stocks are moving in today's after hours session ↗

June 15, 2026

Via Chartmill

Alvotech (NASDAQ:ALVO) Q1 2026 Results Miss Estimates, Shares Drop Over 9% as Revenue and EPS Fall Short ↗

May 06, 2026

Via Chartmill

Alvotech (NASDAQ:ALVO) Reports Q4 Revenue Beat but Significant EPS Miss, Stock Falls on Weak Guidance ↗

March 18, 2026

Via Chartmill

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

June 12, 2026

Driving revenue growth and earnings growth are two different things.

Via The Motley Fool

Topics Intellectual Property

Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions ↗

June 10, 2026

Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilars-focused company is entering a “critical inflection period” as it advances several limited-competition products through...

Via MarketBeat

Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End ↗

June 05, 2026

Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global...

Via MarketBeat

Alvotech (ALVO) Q4 2025 Earnings Transcript ↗

June 02, 2026

Alvotech (ALVO) Q4 2025 Earnings Transcript

Via The Motley Fool

Topics Bonds

Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End ↗

May 13, 2026

Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June...

Via MarketBeat

Alvotech (ALVO) Q1 2026 Earnings Transcript ↗

May 08, 2026

Alvotech (ALVO) Q1 2026 Earnings Transcript

Via The Motley Fool

Wondering what's happening in today's after-hours session? ↗

April 07, 2026

Via Chartmill

Why Is ALVO Stock Rising Pre-Market Today? ↗

February 05, 2026

The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints.

Via Stocktwits

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results....

Via MarketMinute

Topics Bankruptcy Earnings Economy

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug ↗

November 24, 2025

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said.

Via Stocktwits

Ardent Health, KinderCare Learning, Ibotta And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

November 13, 2025

Via Benzinga

Uncovering Potential: Alvotech's Earnings Preview ↗

November 11, 2025

Via Benzinga

This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

November 04, 2025

Via Benzinga

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November ↗

November 04, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

November 03, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Gold Edges Higher; ISM Manufacturing PMI Falls In October ↗

November 03, 2025

Via Benzinga

Alvotech Shares Plunge 33% After FDA Flags Issues ↗

November 03, 2025

Alvotech shares decline after the FDA issues a complete response letter for its Simponi biosimilar, leading to a lower 2025 revenue and EBITDA outlook.

Via Benzinga

Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗

November 03, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.